AdaptHealth (AHCO) to Release Earnings on Tuesday

AdaptHealth (NASDAQ:AHCO) is scheduled to announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of $0.06 per share for the quarter. AdaptHealth has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

AdaptHealth (NASDAQ:AHCO) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.44. AdaptHealth had a positive return on equity of 8.84% and a negative net margin of 21.21%. The business had revenue of $858.23 million for the quarter, compared to analysts’ expectations of $825.94 million. On average, analysts expect AdaptHealth to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

AdaptHealth Stock Performance

Shares of AdaptHealth stock opened at $10.13 on Tuesday. The company has a debt-to-equity ratio of 1.44, a quick ratio of 1.00 and a current ratio of 1.21. AdaptHealth has a 52-week low of $6.37 and a 52-week high of $15.37. The company’s 50 day moving average price is $10.10 and its 200-day moving average price is $8.46.

Insider Activity

In related news, major shareholder James E. Flynn sold 182,607 shares of the business’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $11.02, for a total value of $2,012,329.14. Following the completion of the transaction, the insider now directly owns 11,643,769 shares in the company, valued at approximately $128,314,334.38. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, major shareholder James E. Flynn sold 182,607 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $11.02, for a total transaction of $2,012,329.14. Following the sale, the insider now owns 11,643,769 shares of the company’s stock, valued at approximately $128,314,334.38. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder James E. Flynn sold 52,487 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $10.93, for a total transaction of $573,682.91. Following the transaction, the insider now directly owns 11,826,376 shares of the company’s stock, valued at $129,262,289.68. The disclosure for this sale can be found here. Company insiders own 13.60% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on AHCO shares. Royal Bank of Canada reissued an “outperform” rating and set a $13.00 target price on shares of AdaptHealth in a research note on Monday, March 4th. Jefferies Financial Group lowered shares of AdaptHealth from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $14.50 to $8.00 in a report on Monday, January 8th. Truist Financial raised their target price on shares of AdaptHealth from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, February 28th. Finally, UBS Group boosted their price target on shares of AdaptHealth from $9.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $12.10.

About AdaptHealth

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.